P Dee Stephenson, MD, FACS
2019 OIS
Atia Vision: Company Status

Early stage start-up in the ophthalmology space

Initiated clinical studies

Recently closed $20M financing

A Shifamed Portfolio Company

Highly focused medical innovation hub with a solid track record of success

<table>
<thead>
<tr>
<th>2001</th>
<th>2011</th>
<th>2012</th>
<th>2016</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coronary Artery Disease</td>
<td>Structural Heart Disease</td>
<td>Hypertension</td>
<td>Atrial Fibrillation</td>
<td>Atrial Fibrillation</td>
</tr>
<tr>
<td>Acquired by Boston Scientific</td>
<td>Acquired by Boston Scientific</td>
<td>Acquired by Covidien</td>
<td>Acquired by Abbott/Terumo</td>
<td>Acquired by Boston Scientific</td>
</tr>
</tbody>
</table>
## Evolution of Accommodating IOLs

<table>
<thead>
<tr>
<th>Generation</th>
<th>Description</th>
<th>Challenges</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st Generation</td>
<td>Single Optic Axial Lens Displacement</td>
<td>Limited accommodative response</td>
</tr>
<tr>
<td>2nd Generation</td>
<td>Dual Optic Axial Lens Displacement</td>
<td>Difficult in surgery, Did not meet accommodative endpoints</td>
</tr>
<tr>
<td>3rd Generation</td>
<td>Optic fluid filled, Shape changing single optic</td>
<td>Unpredictable refractive and accommodative outcomes, higher amplitude of accommodation</td>
</tr>
</tbody>
</table>

**Next Frontier**

“Holy Grail” Truly Accommodating Lens
Predictable accommodative & refractive outcomes
**MODULAR DUAL LENS DESIGN**

**SHAPE CHANGING ACCOMMODATING ENGINE**
- Hydraulic multiplier design, mimics the natural dynamic accommodation mechanism of the eye
- Maintains direct contact with open capsular bag for efficient energy transfer from ciliary muscle to the optic

**EXCHANGEABLE FRONT OPTIC**
- Stable optic for refractive predictability
- Addresses each patient’s prescription needs - available in multiple powers and degrees of toricity
- Opportunity for future upgrades as optic technology advances

Aims to restore the full range of functional vision

Designed to prevent visual disturbances & artifacts

Easily exchangeable front optic

Correction of short and long-term refractive issues
**Clinical Summary to Date:**

- Started FIH studies with promising preliminary data
- No significant product-related adverse events
- **Accommodative response**
  - Both subjective and objective measurements showing accommodation

---

Credit to Prof. Igor Solomatin and Dr. Andrei Solomatin
https://drsolomatinisilmakeskus.ee/
Subject 001: UBM Imaging

30 µm cavity height difference observed in Base Component’s fluid chamber
Equates to 1.5D power shift
Subject 001: Subjective Testing Corroborate UBM Result

**Acuity Test**
- DCVA – 0.0 LogMAR (20/20)
- DCIVA – 0.1 LogMAR (20/25)
- DCNVA – 0.1 LogMAR (20/25)

**Defocus Test**

## Large Market Opportunity

- 3.6M cataract procedures performed annually in the US, over 20M worldwide\(^1\)
- Global IOL market expected to reach $5.5B by 2022\(^2\)
- Potential expansion into larger presbyopia market

## Differentiated Solution

- Simplicity of stable, predictable front optic exchange allows for refining both initial and long-term refractive outcomes with future novel optics technology
- Shape changing dynamic accommodation with efficient energy transfer from the ciliary muscles to the optic, not between components

## Milestones

- Completed biocompatibility and preclinical tests for FIH studies
- Completed design verification testing
- Started FIH cases

## Efficient Operations

- Leverage learnings from 1st generation devices
- Proven development process and streamlined resources to deliver high-impact results
- Recently closed on $20M financing

---
